CG Oncology, Inc.

The momentum for this stock is not very good. CG Oncology, Inc. is not a good value stock. CG Oncology, Inc. is not a good growth stock. CG Oncology, Inc. is not very popular among insiders. Tradey thinks it is not wise to invest in CG Oncology, Inc..
Log in to see more information.

News

CG Oncology, Inc. (NASDAQ:CGON) Director Sells $23,000,088.80 in Stock
CG Oncology, Inc. (NASDAQ:CGON) Director Sells $23,000,088.80 in Stock

Ticker Report CG Oncology, Inc. (NASDAQ:CGON - Get Free Report) Director Hong Fang Song sold 650,455 shares of the business's stock in a transaction that occurred on Thursday, August 29th. The shares were sold at...\n more…

CG Oncology, Inc. (NASDAQ:CGON) Receives Average Recommendation of "Buy" from Brokerages
CG Oncology, Inc. (NASDAQ:CGON) Receives Average Recommendation of "Buy" from Brokerages

Zolmax CG Oncology, Inc. (NASDAQ:CGON - Get Free Report) has received a consensus recommendation of "Buy" from the seven ratings firms that are currently covering the company, Marketbeat Ratings reports...\n more…

CG Oncology, Inc. Expected to Earn Q3 2024 Earnings of ($0.43) Per Share (NASDAQ:CGON)
CG Oncology, Inc. Expected to Earn Q3 2024 Earnings of ($0.43) Per Share (NASDAQ:CGON)

Ticker Report CG Oncology, Inc. (NASDAQ:CGON - Free Report) - Roth Capital issued their Q3 2024 EPS estimates for shares of CG Oncology in a research note issued on Tuesday, August 27th. Roth Capital analyst B...\n more…

CG Oncology to Participate in the Morgan Stanley 22nd Annual Global Healthcare Conference
CG Oncology to Participate in the Morgan Stanley 22nd Annual Global Healthcare Conference

Globe Newswire IRVINE, Calif., Aug. 30, 2024 (GLOBE NEWSWIRE) -- CG Oncology, Inc. (NASDAQ: CGON), a late-stage clinical biopharmaceutical company focused on developing and commercializing a potential backbone...\n more…

Research Analysts Offer Predictions for CG Oncology, Inc.'s Q3 2024 Earnings (NASDAQ:CGON)
Research Analysts Offer Predictions for CG Oncology, Inc.'s Q3 2024 Earnings (NASDAQ:CGON)

Zolmax CG Oncology, Inc. (NASDAQ:CGON - Free Report) - Equities researchers at Roth Capital issued their Q3 2024 EPS estimates for CG Oncology in a research note issued on Tuesday, August 27th. Roth...\n more…

CG Oncology (NASDAQ:CGON) Shares Gap Up to $36.51
CG Oncology (NASDAQ:CGON) Shares Gap Up to $36.51

Ticker Report Shares of CG Oncology, Inc. (NASDAQ:CGON - Get Free Report) gapped up before the market opened on Wednesday . The stock had previously closed at $36.51, but opened at $37.41. CG Oncology shares last...\n more…